VTRS
Viatris Inc
NASDAQ: VTRS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$16.92
-0.13% today
Updated 2026-06-05
Market cap
$19.19B
P/E ratio
—
P/S ratio
1.32x
EPS (TTM)
$-0.30
Dividend yield
2.94%
52W range
$8 – $17
Volume
10.7M
WallStSmart proprietary scores
50
out of 100
Grade: C
Hold
Investment rating
3.3
Growth
D5.0
Quality
C+3.5
Profitability
D6.7
Valuation
B4/9
Piotroski F-Score
Moderate
0.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$17.81
+5.26%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy5 Buy4 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $348.40M — positive
Risks
- Altman Z 0.55 — distress zone
- Thin margins at -2.04%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $16.26B | $15.43B | $14.74B | $14.30B | $14.56B |
| Net income | $2.08B | $54.70M | $-634.20M | $-3.51B | $176.40M |
| EPS | — | — | — | — | $-0.30 |
| Free cash flow | $2.51B | $2.33B | $1.98B | $1.94B | $348.40M |
| Profit margin | 12.78% | 0.35% | -4.30% | -24.58% | -2.04% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | LE, GOFF CORINNE | Sale | 39,344 | — |
| 2026-04-15 | LE, GOFF CORINNE | Sale | 3,644 | — |
| 2026-04-15 | LE, GOFF CORINNE | Buy | 39,344 | — |
Peer comparison
Smart narrative
Viatris Inc trades at $16.92. Our Smart Value Score of 50/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.55, it sits in the distress. TTM revenue stands at $14.56B. with profit margins at -2.04%.
Frequently asked questions
What is Viatris Inc's stock price?
Viatris Inc (VTRS) trades at $16.92, on a P/S of 1.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Viatris Inc overvalued?
Viatris Inc carries a Smart Value Score of 50/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Viatris Inc (VTRS)?
The 12-month analyst consensus target is $17.81, about 5.3% above the current $16.92. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Viatris Inc's revenue?
Viatris Inc's trailing twelve-month revenue is $14.56B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Viatris Inc's Altman Z-Score is 0.55, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.32x
ROE-2.02%
Beta0.90
50D MA$15.44
200D MA$12.85
Shares out1.16B
Float1.16B
Short ratio—
Avg volume10.7M
Performance
1 week+0.00%
1 month-3.64%
3 months+17.54%
YTD+27.55%
1 year—
3 years—
5 years—